(Q53236575)

English

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

scientific article published on 21 March 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Enrique Gallardo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

José Luis Pérez-Gracia

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Jose Luis Gonzalez Larriba

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

J Bellmunt

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

C Prior

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

P Maroto

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

D Castellano

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

B Mellado

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

G Aguilar

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

X Villanueva

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

J Albanell

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

21 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

2646-2653

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21427062%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Molecular biology of bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Multiplexed microsphere-based flow cytometric assays

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

The interleukin-8 pathway in cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Interleukin-8 and human cancer biology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR023

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53236575&oldid=1189626782"